U.S. Small Molecule Innovator API CDMO Market Size, Share & Trends Analysis Report By Stage Type (Preclinical, Clinical, Commercial), By Customer Type, By Therapeutic Area, By Region, And Segment Forecasts, 2024 - 2030
This report can be delivered to the clients within 2 Business Days
U.S. Small Molecule Innovator API CDMO Market Growth & Trends
The U.S. small molecule innovator API CDMO market size is anticipated to reach USD 12.60 billion by 2030 and is projected to grow at a CAGR of 6.17% from 2024 to 2030, according to a new report by Grand View Research, Inc. Agrowing outsourcing trend among pharmaceutical companies, increasing demand for small molecule drugs, and surge in clinical trials are anticipated to influence the U.S. market positively.
Small molecules continue to play an important role in developing new treatments globally. Specialty medicines are increasingly driving U.S. pharmaceutical growth, particularly in developed markets, with small molecule applications accounting for over half of specialty sales. In addition, enhanced efficiency serves as another pivotal driver for pharmaceutical outsourcing. With mounting pressure on pharmaceutical companies to expedite the introduction of new drugs to the market, outsourcing emerges as a solution to accelerate the drug development process. Leveraging their expertise, experience, and cutting-edge equipment, CDMOs facilitate the swift & efficient production of high-quality drugs, enabling pharmaceutical firms to adhere to their development schedules.
The pharmaceutical/biotechnology companies increasingly opt for CDMO services to leverage their expertise. CDMOs offer flexibility & scalability in manufacturing capacity, allowing pharmaceutical companies to adapt to changing market demands and accelerate time to market for new therapies. In addition to providing extended expertise and assisting in improved cash flow management, outsourcing brings significant manufacturing advantages, including reducing investment risks. In the context of early-stage technologies and products, establishing expensive in-house capabilities entails substantial risks across the product development phases. At the same time, outsourcing serves as a risk-averse alternative.
The preference for outsourcing small molecule API has grown as an effective strategy until market demand for products becomes well-established and understood. For instance, in May 2022, Piramal Pharma Limited’s Pharma Solutions business, a CDMO, inaugurated a new API facility at its site in Aurora, Ontario. This state-of-the-art plant has commenced operations & has completed its initial production runs.
U.S. Small Molecule Innovator API CDMO Market Report Highlights
U.S. Small Molecule Innovator API CDMO Market Growth & Trends
The U.S. small molecule innovator API CDMO market size is anticipated to reach USD 12.60 billion by 2030 and is projected to grow at a CAGR of 6.17% from 2024 to 2030, according to a new report by Grand View Research, Inc. Agrowing outsourcing trend among pharmaceutical companies, increasing demand for small molecule drugs, and surge in clinical trials are anticipated to influence the U.S. market positively.
Small molecules continue to play an important role in developing new treatments globally. Specialty medicines are increasingly driving U.S. pharmaceutical growth, particularly in developed markets, with small molecule applications accounting for over half of specialty sales. In addition, enhanced efficiency serves as another pivotal driver for pharmaceutical outsourcing. With mounting pressure on pharmaceutical companies to expedite the introduction of new drugs to the market, outsourcing emerges as a solution to accelerate the drug development process. Leveraging their expertise, experience, and cutting-edge equipment, CDMOs facilitate the swift & efficient production of high-quality drugs, enabling pharmaceutical firms to adhere to their development schedules.
The pharmaceutical/biotechnology companies increasingly opt for CDMO services to leverage their expertise. CDMOs offer flexibility & scalability in manufacturing capacity, allowing pharmaceutical companies to adapt to changing market demands and accelerate time to market for new therapies. In addition to providing extended expertise and assisting in improved cash flow management, outsourcing brings significant manufacturing advantages, including reducing investment risks. In the context of early-stage technologies and products, establishing expensive in-house capabilities entails substantial risks across the product development phases. At the same time, outsourcing serves as a risk-averse alternative.
The preference for outsourcing small molecule API has grown as an effective strategy until market demand for products becomes well-established and understood. For instance, in May 2022, Piramal Pharma Limited’s Pharma Solutions business, a CDMO, inaugurated a new API facility at its site in Aurora, Ontario. This state-of-the-art plant has commenced operations & has completed its initial production runs.
U.S. Small Molecule Innovator API CDMO Market Report Highlights
- Based on stage, the clinical segment led the market with the largest revenue share of 54.79% in 2023. The segment growth can be attributed to the rising clinical trial (Phase I-III) activities, growing small molecule development pipeline, and increasing availability of expertise
- Based on the customer type, the pharmaceutical segment held the market with the largest revenue share of 91.89% in 2023, attributing to rising funding for drug development is propelling segment growth
- Based on therapeutic area, the oncology segment accounted for the largest revenue share of 42.05% in 2023. The segment is driven by increasing prevalence of cancer in U.S. In addition, high R&D investments in advanced therapeutics to minimize cancer disease burden are expected to boost segment growth
- West Group dominated the U.S. market with the largest revenue share of 33.19% in 2023. The presence of various factors, such as increasing prevalence of chronic diseases, demand for APIs & CDMO services and improving healthcare infrastructure is expected to drive market significantly
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.1.1. Regional Scope
1.1.2. Estimates and Forecast Timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased Database
1.3.2. GVR’s Internal Database
1.3.3. Secondary Sources
1.3.4. Primary Research
1.3.5. Details of Primary Research
1.4. Information or Data Analysis
1.4.1. Data Analysis Models
1.5. Market Formulation & Validation
1.5.1. Region Wise Market: Base Estimates
1.5.2. Global Market: CAGR Calculation
1.6. Model Details
1.6.1. Commodity Flow Analysis (Model 1)
1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
1.6.3. QFD Model Sizing & Forecasting (Model 3)
1.6.4. Bottom-Up Approach (Model 4)
1.7. Market Definitions
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. Objectives
1.10.1. Objective -
1.10.2. Objective -
1.10.3. Objective -
1.10.4. Objective -
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
CHAPTER 3. U.S. SMALL MOLECULE INNOVATOR API CDMO MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Ancillary Market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing Demand for Small Molecule Drugs
3.2.1.2. Increasing Outsourcing Trends Among Pharmaceutical Companies
3.2.1.3. Surge in Number of Clinical Trials
3.2.2. Market restraint analysis
3.2.2.1. Compliance Issues While Outsourcing
3.3. Technology Landscape
3.3.1. Integration Of AI in U.S. Small Molecule Innovator API CDMO Market
3.3.1.1. Current Dynamics and Future Trends
3.3.1.1.1. Drug Discovery and Design
3.3.1.1.2. AI-Assisted Drug API Synthesis
3.3.1.1.3. Process Optimization
3.3.1.1.4. Supply Chain Management
3.3.1.1.5. Clinical Trial Optimization
3.3.1.1.6. Regulatory Compliance
3.4. Total Number of Clinical Trials in U.S. (2021 - 2023)
3.4.1. Total Number of Clinical Trials by Phase (2021 - 2023)
3.4.2. Total Number of Clinical Trials by Therapeutic Area (2021 - 2023)
3.5. U.S. Small Molecule Innovator API CDMO Market: Regulatory Scenario /Framework
3.6. U.S. Small Molecule Innovator API CDMO Market: Analysis Tools
3.6.1. Porter’s Five Forces Analysis
3.6.2. PESTEL Analysis
3.7. Impact of COVID-19 on Small Molecule Innovator CDMO Market
3.8. COVID-19 Impact Analysis
CHAPTER 4. U.S. SMALL MOLECULE INNOVATOR API CDMO MARKET: STAGE TYPE ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. U.S. Small Molecule Innovator API CDMO Market Movement Analysis
4.3. U.S. Small Molecule Innovator API CDMO Market Size & Trend Analysis, by Stage Type, 2018 to 2030 (USD Million)
4.3.1. Preclinical
4.3.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.3.2. Clinical
4.3.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.3.2.2. Phase I
4.3.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.3.2.3. Phase II
4.3.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.3.2.4. Phase III
4.3.2.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.3.3. Commercial
4.3.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
CHAPTER 5. U.S. SMALL MOLECULE INNOVATOR API CDMO MARKET: CUSTOMER TYPE ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. U.S. Small Molecule Innovator API CDMO Market Movement Analysis
5.3. U.S. Small Molecule Innovator API CDMO Market Size & Trend Analysis, by Customer Type, 2018 to 2030 (USD Million)
5.3.1. Pharmaceutical
5.3.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.3.1.2. Small
5.3.1.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.3.1.3. Medium
5.3.1.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.3.1.4. Large
5.3.1.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.3.2. Biotechnology
5.3.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.3.2.2. Small
5.3.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.3.2.3. Medium
5.3.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.3.2.4. Large
5.3.2.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
CHAPTER 6. U.S. SMALL MOLECULE INNOVATOR API CDMO MARKET: THERAPEUTIC AREA ESTIMATES & TREND ANALYSIS
6.1. Definitions and Scope
6.2. Therapeutic Area Market Share, 2023 & 2030
6.3. Segment Dashboard
6.4. U.S. Small Molecule Innovator API CDMO Market Movement Analysis
6.5. U.S. Small Molecule Innovator API CDMO Market Size & Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
6.5.1. Cardiovascular Diseases
6.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5.2. Oncology
6.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5.3. Respiratory Disorders
6.5.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5.4. Neurology
6.5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5.5. Metabolic Disorders
6.5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5.6. Infectious Diseases
6.5.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5.7. Others
6.5.7.1. Market estimates and forecast 2018 to 2030 (USD Million)
CHAPTER 7. U.S. SMALL MOLECULE INNOVATOR API CDMO MARKET: REGIONAL ESTIMATES & TREND ANALYSIS BY PRODUCT, WORKFLOW, & APPLICATION
7.1. Regional Market Dashboard
7.2. Global Regional Market Snapshot
7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.4. Northeast
7.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.4.2. New Jersey
7.4.2.1. Competitive Scenario
7.4.2.2. Market estimates and forecast, 2018 - 2030 (USD Million)
7.4.3. New York
7.4.3.1. Competitive Scenario
7.4.3.2. Market estimates and forecast, 2018 - 2030 (USD Million)
7.5. Midwest
7.5.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.5.2. Illinois
7.5.2.1. Competitive Scenario
7.5.2.2. Market estimates and forecast, 2018 - 2030 (USD Million)
7.5.3. Missouri
7.5.3.1. Competitive Scenario
7.5.3.2. Market estimates and forecast, 2018 - 2030 (USD Million)
7.6. West Group
7.6.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.6.2. California
7.6.2.1. Competitive Scenario
7.6.2.2. Market estimates and forecast, 2018 - 2030 (USD Million)
7.6.3. Washington
7.6.3.1. Competitive Scenario
7.6.3.2. Market estimates and forecast, 2018 - 2030 (USD Million)
7.7. South
7.7.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.7.2. Texas
7.7.2.1. Competitive Scenario
7.7.2.2. Market estimates and forecast, 2018 - 2030 (USD Million)
7.7.3. Florida
7.7.3.1. Competitive Scenario
7.7.3.2. Market estimates and forecast, 2018 - 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Market Participant Categorization
8.2. Service Heat Map Analysis (a comparative analysis of the players together)
8.3. Company Profiles
8.3.1. Strategy Mapping
8.3.2. Expansion
8.3.3. Partnerships
8.3.4. Acquisitions
8.4. Vendor Landscape
8.4.1. Key company market share analysis, 2023
8.4.2. Lonza Group Ltd.
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Product/service benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Novo Holdings (Catalent, Inc.)
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Product/service benchmarking
8.4.3.4. Strategic initiatives
8.4.4. Thermo Fisher Scientific, Inc.
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Product/service benchmarking
8.4.4.4. Strategic initiatives
8.4.5. Siegfried Holding AG
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Product/service benchmarking
8.4.5.4. Strategic initiatives
8.4.6. Recipharm AB
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Product/service benchmarking
8.4.6.4. Strategic initiatives
8.4.7. CordenPharma International
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Product/service benchmarking
8.4.7.4. Strategic initiatives
8.4.8. Samsung Biologics
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Product/service benchmarking
8.4.8.4. Strategic initiatives
8.4.9. Labcorp
8.4.9.1. Company overview
8.4.9.2. Financial performance
8.4.9.3. Product/service benchmarking
8.4.9.4. Strategic initiatives
8.4.10. Ajinomoto Bio-Pharma Services
8.4.10.1. Company overview
8.4.10.2. Financial performance
8.4.10.3. Product/service benchmarking
8.4.10.4. Strategic initiatives
8.4.11. Piramal Pharma Solutions
8.4.11.1. Company overview
8.4.11.2. Financial performance
8.4.11.3. Product/service benchmarking
8.4.11.4. Strategic initiatives
8.4.12. Jubilant Life Sciences (Jubilant Biosys Limited)
8.4.12.1. Company overview
8.4.12.2. Financial performance
8.4.12.3. Product/service benchmarking
8.4.12.4. Strategic initiatives
8.4.13. WuXi AppTec Co., Ltd.
8.4.13.1. Company overview
8.4.13.2. Financial performance
8.4.13.3. Product/service benchmarking
8.4.13.4. Strategic initiatives
1.1. Market Segmentation & Scope
1.1.1. Regional Scope
1.1.2. Estimates and Forecast Timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased Database
1.3.2. GVR’s Internal Database
1.3.3. Secondary Sources
1.3.4. Primary Research
1.3.5. Details of Primary Research
1.4. Information or Data Analysis
1.4.1. Data Analysis Models
1.5. Market Formulation & Validation
1.5.1. Region Wise Market: Base Estimates
1.5.2. Global Market: CAGR Calculation
1.6. Model Details
1.6.1. Commodity Flow Analysis (Model 1)
1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
1.6.3. QFD Model Sizing & Forecasting (Model 3)
1.6.4. Bottom-Up Approach (Model 4)
1.7. Market Definitions
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. Objectives
1.10.1. Objective -
1.10.2. Objective -
1.10.3. Objective -
1.10.4. Objective -
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
CHAPTER 3. U.S. SMALL MOLECULE INNOVATOR API CDMO MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Ancillary Market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing Demand for Small Molecule Drugs
3.2.1.2. Increasing Outsourcing Trends Among Pharmaceutical Companies
3.2.1.3. Surge in Number of Clinical Trials
3.2.2. Market restraint analysis
3.2.2.1. Compliance Issues While Outsourcing
3.3. Technology Landscape
3.3.1. Integration Of AI in U.S. Small Molecule Innovator API CDMO Market
3.3.1.1. Current Dynamics and Future Trends
3.3.1.1.1. Drug Discovery and Design
3.3.1.1.2. AI-Assisted Drug API Synthesis
3.3.1.1.3. Process Optimization
3.3.1.1.4. Supply Chain Management
3.3.1.1.5. Clinical Trial Optimization
3.3.1.1.6. Regulatory Compliance
3.4. Total Number of Clinical Trials in U.S. (2021 - 2023)
3.4.1. Total Number of Clinical Trials by Phase (2021 - 2023)
3.4.2. Total Number of Clinical Trials by Therapeutic Area (2021 - 2023)
3.5. U.S. Small Molecule Innovator API CDMO Market: Regulatory Scenario /Framework
3.6. U.S. Small Molecule Innovator API CDMO Market: Analysis Tools
3.6.1. Porter’s Five Forces Analysis
3.6.2. PESTEL Analysis
3.7. Impact of COVID-19 on Small Molecule Innovator CDMO Market
3.8. COVID-19 Impact Analysis
CHAPTER 4. U.S. SMALL MOLECULE INNOVATOR API CDMO MARKET: STAGE TYPE ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. U.S. Small Molecule Innovator API CDMO Market Movement Analysis
4.3. U.S. Small Molecule Innovator API CDMO Market Size & Trend Analysis, by Stage Type, 2018 to 2030 (USD Million)
4.3.1. Preclinical
4.3.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.3.2. Clinical
4.3.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.3.2.2. Phase I
4.3.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.3.2.3. Phase II
4.3.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.3.2.4. Phase III
4.3.2.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
4.3.3. Commercial
4.3.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
CHAPTER 5. U.S. SMALL MOLECULE INNOVATOR API CDMO MARKET: CUSTOMER TYPE ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. U.S. Small Molecule Innovator API CDMO Market Movement Analysis
5.3. U.S. Small Molecule Innovator API CDMO Market Size & Trend Analysis, by Customer Type, 2018 to 2030 (USD Million)
5.3.1. Pharmaceutical
5.3.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.3.1.2. Small
5.3.1.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.3.1.3. Medium
5.3.1.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.3.1.4. Large
5.3.1.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.3.2. Biotechnology
5.3.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.3.2.2. Small
5.3.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.3.2.3. Medium
5.3.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
5.3.2.4. Large
5.3.2.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
CHAPTER 6. U.S. SMALL MOLECULE INNOVATOR API CDMO MARKET: THERAPEUTIC AREA ESTIMATES & TREND ANALYSIS
6.1. Definitions and Scope
6.2. Therapeutic Area Market Share, 2023 & 2030
6.3. Segment Dashboard
6.4. U.S. Small Molecule Innovator API CDMO Market Movement Analysis
6.5. U.S. Small Molecule Innovator API CDMO Market Size & Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
6.5.1. Cardiovascular Diseases
6.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5.2. Oncology
6.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5.3. Respiratory Disorders
6.5.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5.4. Neurology
6.5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5.5. Metabolic Disorders
6.5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5.6. Infectious Diseases
6.5.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
6.5.7. Others
6.5.7.1. Market estimates and forecast 2018 to 2030 (USD Million)
CHAPTER 7. U.S. SMALL MOLECULE INNOVATOR API CDMO MARKET: REGIONAL ESTIMATES & TREND ANALYSIS BY PRODUCT, WORKFLOW, & APPLICATION
7.1. Regional Market Dashboard
7.2. Global Regional Market Snapshot
7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.4. Northeast
7.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.4.2. New Jersey
7.4.2.1. Competitive Scenario
7.4.2.2. Market estimates and forecast, 2018 - 2030 (USD Million)
7.4.3. New York
7.4.3.1. Competitive Scenario
7.4.3.2. Market estimates and forecast, 2018 - 2030 (USD Million)
7.5. Midwest
7.5.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.5.2. Illinois
7.5.2.1. Competitive Scenario
7.5.2.2. Market estimates and forecast, 2018 - 2030 (USD Million)
7.5.3. Missouri
7.5.3.1. Competitive Scenario
7.5.3.2. Market estimates and forecast, 2018 - 2030 (USD Million)
7.6. West Group
7.6.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.6.2. California
7.6.2.1. Competitive Scenario
7.6.2.2. Market estimates and forecast, 2018 - 2030 (USD Million)
7.6.3. Washington
7.6.3.1. Competitive Scenario
7.6.3.2. Market estimates and forecast, 2018 - 2030 (USD Million)
7.7. South
7.7.1. Market estimates and forecast, 2018 - 2030 (USD Million)
7.7.2. Texas
7.7.2.1. Competitive Scenario
7.7.2.2. Market estimates and forecast, 2018 - 2030 (USD Million)
7.7.3. Florida
7.7.3.1. Competitive Scenario
7.7.3.2. Market estimates and forecast, 2018 - 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Market Participant Categorization
8.2. Service Heat Map Analysis (a comparative analysis of the players together)
8.3. Company Profiles
8.3.1. Strategy Mapping
8.3.2. Expansion
8.3.3. Partnerships
8.3.4. Acquisitions
8.4. Vendor Landscape
8.4.1. Key company market share analysis, 2023
8.4.2. Lonza Group Ltd.
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Product/service benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Novo Holdings (Catalent, Inc.)
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Product/service benchmarking
8.4.3.4. Strategic initiatives
8.4.4. Thermo Fisher Scientific, Inc.
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Product/service benchmarking
8.4.4.4. Strategic initiatives
8.4.5. Siegfried Holding AG
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Product/service benchmarking
8.4.5.4. Strategic initiatives
8.4.6. Recipharm AB
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Product/service benchmarking
8.4.6.4. Strategic initiatives
8.4.7. CordenPharma International
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Product/service benchmarking
8.4.7.4. Strategic initiatives
8.4.8. Samsung Biologics
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Product/service benchmarking
8.4.8.4. Strategic initiatives
8.4.9. Labcorp
8.4.9.1. Company overview
8.4.9.2. Financial performance
8.4.9.3. Product/service benchmarking
8.4.9.4. Strategic initiatives
8.4.10. Ajinomoto Bio-Pharma Services
8.4.10.1. Company overview
8.4.10.2. Financial performance
8.4.10.3. Product/service benchmarking
8.4.10.4. Strategic initiatives
8.4.11. Piramal Pharma Solutions
8.4.11.1. Company overview
8.4.11.2. Financial performance
8.4.11.3. Product/service benchmarking
8.4.11.4. Strategic initiatives
8.4.12. Jubilant Life Sciences (Jubilant Biosys Limited)
8.4.12.1. Company overview
8.4.12.2. Financial performance
8.4.12.3. Product/service benchmarking
8.4.12.4. Strategic initiatives
8.4.13. WuXi AppTec Co., Ltd.
8.4.13.1. Company overview
8.4.13.2. Financial performance
8.4.13.3. Product/service benchmarking
8.4.13.4. Strategic initiatives
LIST OF TABLES
Table 1 List of abbreviation
Table 2 Northeast Small Molecule Innovator API CDMO market, by States, 2018 - 2030 (USD Million)
Table 3 Northeast Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 4 Northeast Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 5 Northeast Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 6 New Jersey Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 7 New Jersey Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 8 New Jersey Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 9 New York Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 10 New York Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 11 New York Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 12 Midwest Small Molecule Innovator API CDMO market, by States, 2018 - 2030 (USD Million)
Table 13 Midwest Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 14 Midwest Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 15 Midwest Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 16 Illinois Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 17 Illinois Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 18 Illinois Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 19 Missouri Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 20 Missouri Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 21 Missouri Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 22 West Group Small Molecule Innovator API CDMO market, by States, 2018 - 2030 (USD Million)
Table 23 West Group Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 24 West Group Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 25 West Group Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 26 California Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 27 California Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 28 California Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 29 Washington Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 30 Washington Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 31 Washington Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 32 South Small Molecule Innovator API CDMO market, by States, 2018 - 2030 (USD Million)
Table 33 South Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 34 South Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 35 South Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 36 Texas Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 37 Texas Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 38 Texas Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 39 Florida Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 40 Florida Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 41 Florida Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)?
Table 1 List of abbreviation
Table 2 Northeast Small Molecule Innovator API CDMO market, by States, 2018 - 2030 (USD Million)
Table 3 Northeast Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 4 Northeast Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 5 Northeast Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 6 New Jersey Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 7 New Jersey Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 8 New Jersey Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 9 New York Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 10 New York Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 11 New York Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 12 Midwest Small Molecule Innovator API CDMO market, by States, 2018 - 2030 (USD Million)
Table 13 Midwest Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 14 Midwest Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 15 Midwest Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 16 Illinois Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 17 Illinois Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 18 Illinois Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 19 Missouri Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 20 Missouri Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 21 Missouri Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 22 West Group Small Molecule Innovator API CDMO market, by States, 2018 - 2030 (USD Million)
Table 23 West Group Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 24 West Group Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 25 West Group Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 26 California Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 27 California Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 28 California Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 29 Washington Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 30 Washington Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 31 Washington Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 32 South Small Molecule Innovator API CDMO market, by States, 2018 - 2030 (USD Million)
Table 33 South Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 34 South Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 35 South Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 36 Texas Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 37 Texas Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 38 Texas Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 39 Florida Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
Table 40 Florida Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
Table 41 Florida Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)?
LIST OF FIGURES
Fig. 1 U.S. Small molecule innovator API CDMO market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Market formulation & validation
Fig. 7 Commodity flow analysis
Fig. 8 Value-Chain-Based Sizing & Forecasting
Fig. 9 QFD model sizing & forecasting
Fig. 10 Bottom-up approach
Fig. 11 Market snapshot
Fig. 12 Segment snapshot
Fig. 13 Segment snapshot
Fig. 14 Competitive landscape snapshot
Fig. 15 Parent market outlook, 2023(USD Million)
Fig. 16 Ancillary market outlook, 2023 (USD Million)
Fig. 17 U.S. Small molecule innovator API CDMO market dynamics
Fig. 18 FDA’s novel drug approvals in 2023
Fig. 19 Percentage of clinical trials in U.S. by phase, clinical trials and therapeutics areas
Fig. 20 Porter’s five forces analysis
Fig. 21 U.S. Small molecule innovator API CDMO market: PESTEL analysis
Fig. 22 U.S. Small molecule innovator API CDMO market: Stage Type outlook and key takeaways
Fig. 23 U.S. Small molecule innovator API CDMO market: Stage type movement analysis
Fig. 24 Preclinical small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Clinical small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Phase I small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Phase II small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Phase III small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Commercial small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 U.S. Small molecule innovator API CDMO market: Customer type outlook and key takeaways
Fig. 31 U.S. Small molecule innovator API CDMO market: Customer type movement analysis
Fig. 32 Pharmaceutical small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Small pharmaceutical customer in small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 Medium pharmaceutical customer in small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 Large pharmaceutical customer in small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Biotechnology small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Small biotechnology customer in small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Medium biotechnology customer in small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Large biotechnology customer in small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 U.S. Small molecule innovator API CDMO market: Therapeutic area outlook and key takeaways
Fig. 41 U.S. Small molecule innovator API CDMO market: Therapeutic area movement analysis
Fig. 42 Cardiovascular diseases small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 Oncology small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 Respiratory disorders small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 45 Neurology small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 46 Metabolic disorders small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 Infectious diseases small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 Others small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 U.S. Regional market: Key takeaways
Fig. 50 U.S. Regional outlook, 2023 & 2030
Fig. 51 U.S. Regional outlook, 2023 & 2030
Fig. 52 Northeast small molecule innovator API CDMO market, 2018 - 2030 (USD Million)
Fig. 53 New Jersey small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 New York small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Midwest small molecule innovator API CDMO market, 2018 - 2030 (USD Million)
Fig. 56 Illinois small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Missouri small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 58 West Group small molecule innovator API CDMO market, 2018 - 2030 (USD Million)
Fig. 59 California small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 Washington small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 South small molecule innovator API CDMO market, 2018 - 2030 (USD Million)
Fig. 62 Texas small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 Florida small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 64 Market participant categorization
Fig. 65 Heat map analysis
Fig. 66 Market participant categorization
Fig. 1 U.S. Small molecule innovator API CDMO market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Market formulation & validation
Fig. 7 Commodity flow analysis
Fig. 8 Value-Chain-Based Sizing & Forecasting
Fig. 9 QFD model sizing & forecasting
Fig. 10 Bottom-up approach
Fig. 11 Market snapshot
Fig. 12 Segment snapshot
Fig. 13 Segment snapshot
Fig. 14 Competitive landscape snapshot
Fig. 15 Parent market outlook, 2023(USD Million)
Fig. 16 Ancillary market outlook, 2023 (USD Million)
Fig. 17 U.S. Small molecule innovator API CDMO market dynamics
Fig. 18 FDA’s novel drug approvals in 2023
Fig. 19 Percentage of clinical trials in U.S. by phase, clinical trials and therapeutics areas
Fig. 20 Porter’s five forces analysis
Fig. 21 U.S. Small molecule innovator API CDMO market: PESTEL analysis
Fig. 22 U.S. Small molecule innovator API CDMO market: Stage Type outlook and key takeaways
Fig. 23 U.S. Small molecule innovator API CDMO market: Stage type movement analysis
Fig. 24 Preclinical small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Clinical small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Phase I small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Phase II small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 28 Phase III small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 29 Commercial small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 30 U.S. Small molecule innovator API CDMO market: Customer type outlook and key takeaways
Fig. 31 U.S. Small molecule innovator API CDMO market: Customer type movement analysis
Fig. 32 Pharmaceutical small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 33 Small pharmaceutical customer in small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 34 Medium pharmaceutical customer in small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 35 Large pharmaceutical customer in small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 36 Biotechnology small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 37 Small biotechnology customer in small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 38 Medium biotechnology customer in small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 39 Large biotechnology customer in small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 40 U.S. Small molecule innovator API CDMO market: Therapeutic area outlook and key takeaways
Fig. 41 U.S. Small molecule innovator API CDMO market: Therapeutic area movement analysis
Fig. 42 Cardiovascular diseases small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 43 Oncology small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 44 Respiratory disorders small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 45 Neurology small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 46 Metabolic disorders small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 47 Infectious diseases small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 48 Others small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 49 U.S. Regional market: Key takeaways
Fig. 50 U.S. Regional outlook, 2023 & 2030
Fig. 51 U.S. Regional outlook, 2023 & 2030
Fig. 52 Northeast small molecule innovator API CDMO market, 2018 - 2030 (USD Million)
Fig. 53 New Jersey small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 54 New York small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 55 Midwest small molecule innovator API CDMO market, 2018 - 2030 (USD Million)
Fig. 56 Illinois small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 57 Missouri small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 58 West Group small molecule innovator API CDMO market, 2018 - 2030 (USD Million)
Fig. 59 California small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 60 Washington small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 61 South small molecule innovator API CDMO market, 2018 - 2030 (USD Million)
Fig. 62 Texas small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 63 Florida small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 64 Market participant categorization
Fig. 65 Heat map analysis
Fig. 66 Market participant categorization
